Skip to content
Bored Studies
RecruitingAccepts healthy volunteersEarly Phase 1

Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction

Medical College of Wisconsin · NCT05593549

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–80 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Early Phase 1
Target enrollment
60
US sites recruiting
1
Study start
January 1, 2023
Record last updated
October 30, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this clinical trial is to examine the role of autophagy on microvascular function in adults with Type 2 Diabetes. The main question it aims to answer are:

  • Does presence of Type 2 Diabetes reduce autophagy and impair microvascular function?
  • Does exposure to high glucose impair autophagy and subsequently microvascular function?

Participants will undergo 2 study days. The primary outcome will be in vivo microvascular function testing. Following the first study day participants will undergo either supplementation with trehalose, an autophagy activator, or placebo for 14 days. The second study day will test in vivo microvascular function.

Being studied: Trehalose; Placebo

Conditions: Type 2 Diabetes; Healthy Aging

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria: Participants must be between 18-80 yrs. of age and will be delineated into two groups

  • Clinical Diagnosis of Type 2 Diabetes Mellitus in accordance with American Diabetes Association (ADA) guidelines (Type 2 Diabetic group)
  • Otherwise healthy individuals (Healthy control group) with no more than 1 cardiovascular risk factor

Exclusion Criteria

  • Uncontrolled hypertension
  • Current Tobacco use or within last 6 months
  • BMI > 35
  • Hyperlipidemia
  • Hypercholesterolemia
  • Type 1 Diabetes
  • Use of anti-coagulant drugs, or anti-platelet drugs
  • Symptomatic coronary artery disease
  • Heart Failure
  • Renal Impairment
  • Hormone Replacement Therapy
  • History of Retinopathy
  • Documented Neuromuscular Disorders
  • Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
  • Pregnancy (Young Female subjects)
  • Allergies to Povidone Iodine
  • Use Erectile Dysfunction Medication in the past 6 months
  • Use of Topical/non-topical Steroids in last 6 months
  • Active Anti-Cancer Treatment or Treatment within last 12 months
  • Active COVID-19 or within the past 3 months
  • Gender Reassignment Therapy

Recruiting US locations

  • Medical College of Wisconsin

    Milwaukee, WI 53226

    Site contact: William Hughes, Ph.D. · whughes@mcw.edu

Study contacts (from the official record)

  • William Hughes, Ph.D. · 414-955-7519 · whughes@mcw.edu
All diabetes studies in Wisconsin →
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction (NCT05593549) | Bored Studies